Cardiac Outcomes of Subjects on Adjuvant Trastuzumab Emtansine Vs Paclitaxel in Combination with Trastuzumab for Stage I HER2-positive Breast Cancer (ATEMPT) Study (TBCRC033): a Randomized Controlled Trial
Romualdo Barroso-Sousa,Paolo Tarantino,Nabihah Tayob,Chau Dang,Denise A. Yardley,Steven J. Isakoff,Vicente Valero,Meredith Faggen,Therese Mulvey,Ron Bose,Jiani Hu,Douglas Weckstein,Antonio C. Wolff,Katherine Reeder-Hayes,Hope S. Rugo,Bhuvaneswari Ramaswamy,Dan Zuckerman,Lowell Hart,Vijayakrishna K. Gadi,Michael Constantine,Kit Cheng,Frederick Briccetti,Bryan Schneider,Audrey Merrill Garrett,Kelly Marcom,Kathy Albain,Patricia DeFusco,Nadine Tung,Blair Ardman,Rita Nanda,Rachel C. Jankowitz,Mothaffar Rimawi,Vandana Abramson,Paula R. Pohlmann,Catherine Van Poznak,Andres Forero-Torres,Minetta Liu,Kathryn J. Ruddy,Yue Zheng,Shoshana M. Rosenberg,Richard D. Gelber,Lorenzo Trippa,William Barry,Michelle DeMeo,Harold Burstein,Ann Partridge,Eric P. Winer,Ian Krop,Sara M. Tolaney
DOI: https://doi.org/10.1038/s41523-022-00385-2
2022-01-01
npj Breast Cancer
Abstract:The excellent outcomes seen in patients treated with adjuvant trastuzumab emtansine (T-DM1) in the ATEMPT trial and the favorable toxicity profile associated with this agent make T-DM1 a potential therapeutic option for select patients with stage I HER2-positive breast cancer. Moreover, T-DM1 is an established adjuvant treatment for patients with HER2-positive breast cancer with the residual invasive disease after neoadjuvant therapy. Given that cardiotoxicity is the most significant adverse event of trastuzumab, which is a main molecular component of T-DM1, we conducted a sub-analysis of the ATEMPT trial to determine the cardiac safety of adjuvant T-DM1. In this analysis, the incidence of grade 3–4 left ventricular systolic dysfunction (LVSD) in T-DM1 or trastuzumab plus paclitaxel arms were respectively 0.8 and 1.8%. In addition, three (0.8%) patients in the T-DM1 arm and six (5.3%) patients in the adjuvant paclitaxel with trastuzumab (TH) arm experienced a significant asymptomatic left ventricular ejection fraction (LVEF) decline that per-protocol required holding T-DM1 or trastuzumab. All patients with available follow-up data experienced full resolution of cardiac symptoms and LVEF normalization. Furthermore, we performed an exploratory analysis to assess the relationship between age, baseline LVEF, and body mass index with cardiac outcomes. No significant association between these baseline characteristics and the incidence of significant asymptomatic LVEF decline or symptomatic LVSD was identified. The low incidence of significant cardiac adverse events in this population during therapy with adjuvant T-DM1 suggests that studies on the cost-effectiveness of cardiac monitoring during adjuvant therapy using anthracycline-free regimens are needed. Clinical Trial Registration: ClinicalTrials.gov, NCT01853748